

1 [Category: Study Protocol]

2 Sequential Bilateral Accelerated Theta Burst Stimulation in Adolescents

3 With Suicidal Ideation Associated With Major Depressive Disorder:

4 Protocol for a Randomized Controlled Trial

5 Deniz Yuruk, MD

6 Can Ozger

7 Juan F. Garzon, MD

8 Jarrod M. Leffler, PhD

9 Julia Shekunov, MD

10 Jennifer L. Vande Voort, MD

11 Michael J. Zaccariello, PhD, LP

12 Paul A. Nakonezny, PhD

13 Paul E. Croarkin, DO, MS

14

15

16 **Author Affiliations:** Research Fellow in the Department of Psychiatry and

17 Psychology (Yuruk and Garzon), Mayo Clinic School of Graduate Medical

18 Education, Mayo Clinic College of Medicine and Science, Rochester,

19 Minnesota; Virginia Treatment Center for Children (Leffler), Virginia

20 Commonwealth University, Richmond, Virginia; Clinical Research

21 Coordinator in the Department of Psychiatry and Psychology (Ozger),

22 Department of Psychiatry and Psychology (Shekunov, Vande Voort,

23 Zaccariello, and Croarkin), Mayo Clinic Children's Research Center (Vande

24 Voort, Zaccariello, and Croarkin), and Mayo Clinic Depression Center

25 (Vande Voort and Croarkin), Mayo Clinic, Rochester, Minnesota; and

26 Department of Population and Data Sciences (Nakonezny), UT  
27 Southwestern Medical Center, Dallas, Texas.  
28 **Corresponding Author:** Paul E. Croarkin, DO, MS, Department of  
29 Psychiatry and Psychology, Mayo Clinic, 200 First St SW, Rochester, MN  
30 55905 (croarkin.paul@mayo.edu).  
31 Text word count: 6,996  
32 Abstract word count: 289  
33 No. of tables: 2  
34 No. of figures: 1  
35 No. of boxes: 1  
36 No. of appendixes: 3  
37 Short title: aTBS in Suicidal Adolescents  
38

39

## Abstract

40 **Background:** Suicide is a leading cause of death in adolescents worldwide.

41 Previous research findings suggest that suicidal adolescents with depression

42 have pathophysiological dorsolateral prefrontal cortex (DLPFC) deficits in

43  $\gamma$ -aminobutyric acid neurotransmission. Interventions with transcranial

44 magnetic stimulation (TMS) directly address these underlying

45 pathophysiological deficits in the prefrontal cortex. Theta burst stimulation

46 (TBS) is newer dosing approach for TMS. Accelerated TBS (aTBS)

47 involves administering multiple sessions of TMS daily as this dosing may be

48 more efficient, tolerable, and rapid acting than standard TMS.

49 **Methods:** This is a randomized, double-blind, sham-controlled trial of

50 sequential bilateral aTBS in adolescents with MDD and suicidal ideation.

51 Three sessions are administered daily for 10 days. During each session,

52 continuous TBS is administered first to the right DPFC, in which 1,800

53 pulses are delivered continuously over 120 seconds. Then intermittent TBS

54 is applied to the left DPFC, in which 1,800 pulses are delivered in 2-second

55 bursts and repeated every 10 seconds for 570 seconds. The TBS parameters

56 were adopted from prior research, with 3-pulse, 50-Hz bursts given every

57 200 ms (at 5 Hz) with an intensity of 80% active motor threshold. The

58 comparison group will receive 3 daily sessions of bilateral sham TBS

59 treatment for 10 days. All participants will receive the standard of care for

60 patients with depression and suicidal ideation including daily

61 psychotherapeutic skill sessions. Long-interval intracortical inhibition (LICI)

62 biomarkers will be measured before and after treatment. Exploratory

63 measures will be collected with TMS and electroencephalography for

64 biomarker development.

65 **Discussion:** This is the first known randomized controlled trial to examine  
66 the efficacy of sequential bilateral aTBS for treating suicidal ideation in  
67 adolescents with MDD. Results from this study will also provide  
68 opportunities to further understand the neurophysiological and molecular  
69 mechanisms of suicidal ideation in adolescents.

70 **Trial registration:** Investigational device exemption (IDE) Number:  
71 G200220, ClinicalTrials.gov (ID: NCT04701840). Registered August 6,  
72 2020.  
73 <https://clinicaltrials.gov/ct2/show/NCT04502758?term=NCT04701840&dra>  
74 [w=2&rank=1](https://clinicaltrials.gov/ct2/show/NCT04502758?term=NCT04701840&dra)

75

76 **Keywords:** accelerated theta burst stimulation; adolescent; depression;  
77 neuromodulation; suicidal ideation; suicide; transcranial magnetic  
78 stimulation

79

80

## Abbreviations

- 81 AE, adverse event
- 82 aTBS, accelerated theta burst stimulation
- 83 CDRS-R, Children’s Depression Rating Scale Revised
- 84 CRF, case report form
- 85 C-SSRS, Columbia–Suicide Severity Rating Scale
- 86 DPFC, dorsolateral prefrontal cortex
- 87 DSMB, Data and Safety Monitoring Board
- 88 EEG, electroencephalography
- 89 EMG, electromyography
- 90 FDA, US Food and Drug Administration
- 91 GABA,  $\gamma$ -aminobutyric acid
- 92 GEE, generalized estimating equation
- 93 HIPAA, Health Insurance Portability and Accountability Act
- 94 IDE, investigational device exemption
- 95 IRB, institutional review board
- 96 LICI, long-interval intracortical inhibition
- 97 LICI-100, LICI at an interstimulus interval of 100 ms
- 98 MDD, major depressive disorder
- 99 MINI-KID, Mini-International Neuropsychiatric Interview for Children and
- 100 Adolescents
- 101 MNAR, missing not at random
- 102 MT, motor threshold
- 103 N45, 45 ms after stimulation
- 104 N100, 100 ms after stimulation
- 105 NDA, US National Institute of Mental Health Data Archive

- 106 NIH, US National Institutes of Health
- 107 NIMH, US National Institute of Mental Health
- 108 OR, odds ratio
- 109 PHI, protected health information
- 110 PI, principal investigator
- 111 SAE, serious adverse event
- 112 TBS, theta burst stimulation
- 113 TMS, transcranial magnetic stimulation
- 114 UADE, unanticipated adverse device effect
- 115

116

## Introduction

117

Suicide is a leading cause of death in adolescents worldwide [1-3].

118

In the US, 18% of teenagers report seriously considering suicide, 15% have

119

made a suicide plan, and 9% have attempted suicide within the preceding

120

year [4,5]. Effective treatments of suicidal ideation are limited for

121

adolescents with major depressive disorder (MDD) [6-8]. Previous research

122

focused on understanding the risk factors for suicide in adolescents in

123

attempted to reduce their overall suicide rates [4,8-10]. Despite decades of

124

research, however, the predictive value of identified suicide risk factors is

125

low and has not improved substantially [8]. Biological correlates explored to

126

date are also weak predictors of suicidal behaviors [8,11-13]. Little prior

127

research has focused on rapid-acting treatments for adolescents with MDD

128

who are actively struggling with thoughts of suicide or have recently

129

attempted suicide [7,14]. Although some studies explored the antisuicidal

130

effects of alternative treatments in adult populations, a considerable

131

knowledge gap remains regarding treating adolescents at risk for suicide

132

[8,15,16].

133

Suicidal persons have structural, functional, neurophysiological,

134

and neuroplastic alterations in the dorsolateral prefrontal cortex (DPFC) [17-

135

19], and these alterations may be targeted with neurostimulation. Structural

136

alterations and serotonergic dysfunction in the DPFC are associated with

137

lethality of suicide attempts [19-21]. Suicidal persons also have

138

abnormalities in processing negative emotional stimuli and in activating the

139

DPFC. These findings for DPFC activation vary across studies, suggesting

140

multiple neural phenotypes of suicidality that are poorly understood [19].

141

Previous research findings suggest that suicidal adolescents with depression

142 have pathophysiological DPFC deficits in  $\gamma$ -aminobutyric acid (GABA)  
143 function [22-25]. Impaired prefrontal cortical GABAergic inhibitory gating  
144 related to depression may reduce an adolescent's control over their thoughts  
145 and behaviors and may culminate in suicidal ideation and behaviors  
146 [17,26,27]. Interventions with transcranial magnetic stimulation (TMS)  
147 directly address these underlying pathophysiological deficits in the DPFC  
148 [28,29].

149           In the past decade, studies of TMS interventions found that  
150 bilateral TMS strongly reduced suicidal ideation in adults with MDD  
151 [30,31]. Preliminary research involving TMS to treat adolescents' suicidal  
152 ideation has shown promising results [14]. Treatment with TMS most likely  
153 addresses pathological imbalances in prefrontal cortical GABAergic  
154 inhibitory function that underlie depression and suicidal ideation in  
155 adolescents [14,22,23,29,32]. Standard 10-Hz TMS, however, does not  
156 typically produce rapid relief from suicidal ideation and depressive  
157 symptoms [31,33,34].

158           A newer type of TMS, termed *theta burst stimulation* (TBS),  
159 induces changes in synaptic plasticity more rapidly than standard TMS [35-  
160 40]. Protocols with TBS appear to be safe in adolescents, are more tolerable  
161 than standard TMS, and are delivered over approximately 12-minute  
162 sessions vs 37-minute sessions with standard TMS [41,42]. TBS was  
163 developed by mirroring endogenous hippocampal discharges [37]. In TBS  
164 dosing, 3-pulse, 50-Hz bursts are delivered every 200 ms (at 5 Hz).  
165 Stimulation with intermittent TBS has been shown to produce long-term  
166 potentiation-like effects [37,43,44], and continuous TBS reduces cortical  
167 excitability [37,45]. In prior studies of sequential bilateral TBS, continuous



168 TBS was delivered during each session to the right prefrontal cortex,  
169 followed by intermittent TBS delivered to the left prefrontal cortex [41,46].  
170 This technique is thought to target hypoactivity of the left DPFC and  
171 hyperactivity of the right DPFC associated with MDD and suicidal ideation  
172 [19,47,48]. Prior studies suggest that sequential bilateral TBS approaches  
173 clinically reduce depressive symptoms and suicidal ideation more than  
174 unilateral TBS [30,31,46].

175           Accelerated TBS (aTBS) dosing delivers multiple daily sessions  
176 of TBS [49]. The rationale for accelerated dosing is that multiple  
177 stimulations each day will produce faster, greater, and more durable  
178 effectiveness than standard, daily TMS sessions. Studies of aTBS dosing for  
179 adult patients with refractory depression have had encouraging results  
180 [36,40]. Few prior studies have investigated the use of TBS and aTBS  
181 protocols in adolescents. However, the safety profile for adolescents appears  
182 to be similar to that for adults [41]. Prior study findings suggest that repeated  
183 TBS sessions safely enhance neurophysiological and clinical changes  
184 [41,42,50]. Recent work suggests that aTBS protocols more rapidly and  
185 effectively improve depressive symptoms and improve synaptic plasticity in  
186 the prefrontal cortex [36,39,40]. These aTBS protocols also overcome many  
187 practical limitations of standard TMS [49].

188           Integrating TMS with electromyography (EMG) or  
189 electroencephalography (EEG) in neurophysiological studies facilitates the  
190 study of cortical inhibition biomarkers and related neurotransmission [51-  
191 53]. Short-interval intracortical inhibition indexes cortical GABA<sub>A</sub>-mediated  
192 inhibitory neurotransmission, and long-interval intracortical inhibition  
193 (LICI) indexes the cortical GABA<sub>B</sub>-mediated inhibitory neurotransmission

194 [53-55]. Data collected with TMS-EEG may yield more direct measures of  
195 prefrontal cortical function, but some contemporary methods are  
196 controversial [56-60], and TMS-EEG measures have not been reliably  
197 collected in adolescents with depression and suicidal ideation [59].  
198 Conversely, with TMS-EMG, measures of prefrontal cortical function have  
199 been extensively studied in adolescents with depression and could easily be  
200 implemented in clinical environments [24,51,61-63]. Adolescents with  
201 MDD and suicidal behaviors have deficient LICI with related GABA<sub>B</sub>  
202 impairment [25]. A preliminary study found that in adolescents treated for  
203 depression, LICI markers improve, with concurrent decrements in suicidal  
204 ideation [64]. Hence, TMS-EMG measures of LICI provide a promising  
205 biomarker for assessing and treating adolescents with depression and  
206 suicidal ideation.

### 207 ***Objectives***

208           The primary aim of this randomized controlled clinical trial is to  
209 compare the efficacy of sequential bilateral aTBS vs sham stimulation for  
210 treating suicidal ideation in adolescents with MDD. It is hypothesized that,  
211 compared with sham stimulation, sequential bilateral aTBS will provide  
212 greater improvements in intensity of suicidal ideation over the 10-day  
213 treatment course (hypothesis 1a) and over the 12-month follow-up period  
214 (hypothesis 1b) and would lead to fewer emergency department visits and  
215 fewer hospitalizations related to suicidality during 12-month follow-up  
216 (hypothesis 1c).

217           The secondary aim examines LICI, measured with TMS-EMG, as  
218 a predictive and target engagement biomarker for suicidality in adolescents  
219 with MDD. It is hypothesized cortical inhibition will demonstrate an

220 indirect correlation with severity of suicidal ideation at baseline (hypothesis  
221 2a) and over the 10-day treatment (hypothesis 2b). An exploratory aim  
222 examines the use TMS integrated with EEG (rather than EMG) to develop  
223 measures of cortical inhibition for assessing suicide risk and responsiveness  
224 to aTBS in adolescents with MDD (hypothesis 3). This concurrent TMS-  
225 EEG research will provide opportunities to further our understanding of the  
226 neurophysiological and molecular mechanisms of suicidal ideation in  
227 adolescents while refining biomarker methodology for future clinical use  
228 [60,61].

## 229 **Methods**

### 230 ***Design and Study Setting***

231 This is a randomized, double-blind, sham-controlled trial of  
232 sequential bilateral aTBS in adolescents with depression and suicidal  
233 ideation. This study follows an experimental medicine approach [65]  
234 implemented in an intensive outpatient program setting that supports local  
235 emergency departments, an 18-bed adolescent inpatient psychiatry unit, and  
236 outpatient clinics. The study is taking place at Mayo Clinic, Rochester,  
237 Minnesota, and the schedule of events is shown in the Figure.

### 238 ***Eligibility Criteria***

239 This study is enrolling adolescents with MDD and suicidal  
240 ideation in both the treatment group and control (sham) group. Both  
241 inpatients and outpatients are eligible to participate if they meet the inclusion  
242 criteria shown in the Box and have none of the exclusion criteria listed there.  
243 Use of antidepressant medication (if recommended by the referring clinician  
244 and agreed on by the parent/guardian and patient) is allowed.

### 245 ***Intervention***

246                   The TMS system (MagVenture TMS Therapy, MagVenture Inc)  
247 used in this study is cleared by the US Food and Drug Administration (FDA)  
248 for treatment of MDD in adult patients who did not receive satisfactory  
249 improvement from antidepressant medication in the current depressive  
250 episode. This TMS protocol delivers intermittent TBS for 3 minutes and is  
251 based on a patterned TMS paradigm delivered to the left DPFC at 120%  
252 resting motor threshold (MT). It consists of bursts of 3 pulses at 50 Hz with  
253 bursts repeated at 5 Hz in a duty cycle of 2 seconds on, 8 seconds off over 3  
254 minutes 9 seconds, for a total of 600 pulses. Treatment typically is  
255 administered daily for 5 days per week, for 4 to 6 weeks.

256                   In the present study, TBS will be delivered on both the right and  
257 left DPFC, 3 times daily for 10 days (5 days per week). During each session,  
258 *continuous* TBS, in which 1,800 pulses will be delivered continuously over  
259 120 seconds, is administered first to the right DPFC. Then intermittent TBS  
260 is administered to the left DPFC, with 1,800 pulses delivered in 2-second  
261 bursts and repeated every 10 seconds for 570 seconds. The comparison  
262 group will receive 3 daily sessions of bilateral sham TBS for 10 days. The  
263 system has both active and placebo (sham) coils (MagVenture Cool-B70  
264 A/P coils, MagVenture Inc). Because of the nature of the accelerated  
265 treatment paradigm and the age of the target population (13-18 years), the  
266 intensity will be decreased from the usual 120% MT to 80% MT. The TBS  
267 parameters were adopted from prior research [41].

268                   During the trial, all participants will receive standard-of-care  
269 treatment of depression and suicidal ideation, including daily  
270 psychotherapeutic skill sessions during TBS therapy [7,66]. The 10-day

271 psychotherapy treatment program was adapted from a youth suicide  
272 prevention program [66].

### 273 *Discontinuing or Modifying Allocated Interventions*

274 Participants may withdraw voluntarily from the study at any time.  
275 The participant stopping rules apply during the 2-week period when the  
276 participants are receiving the study intervention (active or sham sequential  
277 bilateral aTBS). These rules do not apply to participants in the naturalistic 1-  
278 year follow-up portion of the study. Participants will be withdrawn from the  
279 study by the PI (Principal Investigator) if they have any of the following:

- 280 • A seizure
- 281 • Treatment-induced mania as confirmed by *Diagnostic and Statistical*  
282 *Manual of Mental Disorders* (Fifth Edition) definitions
- 283 • Psychotic symptoms
- 284 • Noncompliance with study procedures
- 285 • Illicit drug use or a positive urine drug screen during the study

### 286 *Strategies to Improve Adherence to Interventions*

287 All participants will be provided with an intensive, 10-day  
288 psychotherapeutic intervention during the trial of sequential bilateral aTBS  
289 [41,66,67]. This psychotherapeutic program meets and exceeds both local  
290 and national standards of care for depressed adolescents with suicidal  
291 ideation.

292 Our prior experience suggests that the sequential bilateral aTBS  
293 protocol in the present study will facilitate participant retention because it is  
294 a more pragmatic schedule with 10 treatment days total. Mayo Clinic's  
295 neuromodulation research team can offer treatment sessions over the  
296 weekend if necessary to accommodate an adolescent's or family's schedule.

297 *Concomitant Care During the Trial*

298           During the trial, participants will continue to take antidepressant  
299 medication if recommended by their referring clinician. Participants are not  
300 required to take antidepressant medication for study participation because of  
301 ethical, human subject protection, and practical concerns. During the  
302 treatment phase, zaleplon, zolpidem, or zopiclone (1 dose nightly) as needed  
303 for treatment-emergent insomnia or lorazepam (up to 2 mg/d) for treatment-  
304 emergent anxiety may be administered for up to 10 doses. The use of  
305 alternative hypnotics or anxiolytic compounds requires prior approval from  
306 the PI. Hormonal contraceptives are allowed. Short-term treatments of  
307 headache, allergy, viral rhinitis, and influenza symptoms will be allowed  
308 during the trial. All questions regarding the acceptability of specific  
309 medications must be answered by the PI.

310 *Provisions for Posttrial Care After Withdrawal*

311           The PI will assist with clinical referrals for all participants who  
312 voluntarily withdraw from the study or are withdrawn by the research team  
313 and PI. Specifically, the PI will offer ongoing clinical care or community  
314 referrals depending on the participant's preference.

315 ***Outcomes***

316           The primary outcome is efficacy of sequential bilateral aTBS vs  
317 sham stimulation for reducing suicidal ideation in adolescents with MDD.  
318 The primary acute outcome measure is change in the score of the Columbia-  
319 Suicide Severity Rating Scale (C-SSRS) severity of ideation subscale [68]  
320 over the 10-day treatment. Additional outcome measures include monthly  
321 follow-up C-SSRS severity of ideation subscale scores, number of  
322 hospitalizations related to suicidal ideation, and number of emergency

323 department visits related to suicidal ideation over the 12-month follow-up  
324 period.

325           The secondary outcome is to examine LICI as a predictive and  
326 target-engagement biomarker for suicidality in adolescents with MDD.  
327 Suicidal ideation will be measured with the C-SSRS severity of ideation  
328 subscale, and cortical inhibition will be assessed by using LICI at an  
329 interstimulus interval of 100 ms (LICI-100) collected with TMS-EMG at  
330 baseline and at the end of the 10-day treatment.

331           An exploratory outcome is developing TMS-EEG measures of  
332 cortical inhibition (TMS-EEG at 45 ms after stimulation [N45] and 100 ms  
333 after stimulation [N100]) for assessing suicide risk and responsiveness to  
334 aTBS in adolescents with MDD.

### 335 ***Participant Timeline***

336           The schedule of enrollment, interventions, assessments, and visits  
337 is shown in Table 1. The first visit for study participants is a screening visit.  
338 At this visit, informed consent and assent will be completed. A medical  
339 history will be taken, vital signs (pulse, blood pressure, temperature, height,  
340 and weight) will be measured, and a physical examination, urine pregnancy  
341 test (if applicable), and urine drug screen will be completed. The  
342 participant's parent or guardian will not be told the pregnancy test result  
343 without the participant's permission, but if the study physician believes that  
344 the pregnancy may cause serious health problems, they may need to tell the  
345 parent or guardian the test results. Patients with a positive urine drug screen  
346 that is not due to prescribed medications are ineligible for study  
347 participation. The study physician will ask if the results can be shared with  
348 the parent or guardian. This information will be kept confidential if the

349 participant chooses not to share the drug test results with the parent or  
350 guardian. The result from the urine drug test will not become part of the  
351 medical record, but the results will remain in the study record.

352 Additional screening assessments (Table 2) include the  
353 Transcranial Magnetic Stimulation Safety Screen [69], Antidepressant  
354 Treatment History Form [70], Pubertal Development Scale [71], Mini-  
355 International Neuropsychiatric Interview for Children and Adolescents  
356 (MINI-KID) for participants aged 12 to 17 years [72] or the Mini-  
357 International Neuropsychiatric Interview for participants aged 18 years [73],  
358 Young Mania Rating Scale [74], Children’s Depression Rating Scale  
359 Revised (CDRS-R) [75], C-SSRS [68], Beck Depression Interview-II [76],  
360 and Clinical Global Impressions–Severity Scale [77]. Also discussed and  
361 noted at the screening visit are concurrent use of medications, adverse events  
362 (AEs), serious AEs (SAEs), the case report form (CRF), and concurrent  
363 psychotherapy. The screening visit can occur on the same day or across 2  
364 consecutive days depending on participant preference.

365 After eligibility is confirmed, additional assessments will be  
366 completed at a subsequent visit. These assessments include the NIH (US  
367 National Institutes of Health) Toolbox Cognition Battery [78] and a  
368 pretreatment expectations survey. The Young Mania Rating Scale, CDRS-R,  
369 C-SSRS, and Beck Depression Interview-II will be repeated, and concurrent  
370 use of medications, concurrent psychotherapy, and CRFs will be reviewed.  
371 During the intervention period, AEs and SAEs will be recorded. TMS  
372 neurophysiological data also will be collected.

373 After acceptance into the trial, each participant is randomly  
374 assigned to either the active aTBS group or sham aTBS, as described in the



375 Randomization and Blinding section. Coil localization (Beam F3 method)  
376 and MT procedures are completed [79]. The participant will complete day 1  
377 of aTBS as assigned (either 3 active sequential bilateral TBS sessions or 3  
378 bilateral sham sessions). Treatment continues for 9 more days if tolerated.

### 379 *Sample Size*

380           Based on prior experience, it is anticipated that 200 patients will  
381 be screened and 100 will be enrolled to reach the target sample size of 80  
382 needed to complete this pilot study. The sample size for the primary  
383 outcome (suicidal ideation over 10 days of sequential bilateral aTBS  
384 treatment) was estimated by incorporating a repeated-measures design with  
385 assumptions about potential participants (eg, effect size, odds ratio [OR]).  
386 These assumptions were based on a 2018 study of the effect of bilateral  
387 repetitive TMS vs sham stimulation on suicidal ideation in adult patients  
388 with treatment-resistant MDD [31]. The results from the a priori sample size  
389 estimation and power analysis suggested that a sample size of 35 participants  
390 per group (N=70) would achieve 80% power at a .05  $\alpha$  level (2-tailed) [31].  
391 The aim is to detect an overall OR of 2.85 for the primary outcome of less  
392 suicidal ideation with sequential bilateral aTBS vs sham stimulation in a 2-  
393 group (between-participants) randomized design. The posited OR is based  
394 on 10 (within-participants) repeated measurements of severity of suicidal  
395 ideation on the CSSR-S subscale, when the proportion (incident rate) of  
396 suicidal ideation from the sham group at the end of the 10-day trial meets or  
397 exceeds 0.50 and the assumed within-participant correlation between  
398 observations (suicide ideation) for the same participant is 0.50 or less. (A  
399 correlation of 0.50 was based on guidance from our preliminary study of  
400 TMS [14].) The posited OR of 2.85 for the current application is slightly

401 more conservative than what was reported in a study by Weissman et al [31]  
402 of effects of bilateral TMS vs sham stimulation on suicidal ideation in adult  
403 patients with treatment-resistant MDD (OR=3.03).

404 The dropout rate is estimated to be 10%, an approximation based  
405 on treatment discontinuation results from our previous repetitive TMS  
406 studies [14,80,81]. Thus, 80 participants will be enrolled to allow for this  
407 expected rate of attrition with the intent of capturing evaluable data for 70  
408 participants. PASS (Power Analysis and Sample Size) 2019 software version  
409 14.0.15 (NCSS) was used to perform the sample size and power analysis.

410 To definitively evaluate the effect of sequential bilateral aTBS  
411 treatment on suicidal ideation in adolescents, we may require a sample size  
412 larger than 70. The treatment effect of sequential bilateral aTBS has not been  
413 previously studied in adolescents with suicidal depression, and we have no  
414 previous findings from an adolescent population to guide effect size  
415 selection for the present effort. The selection of 70 participants was, in part,  
416 resource driven. The sample size is designed to detect a moderate effect and  
417 to establish a proof of concept so that the research can expand to a  
418 subsequent, larger-scale multicenter study. Nevertheless, the current pilot  
419 study permits an evaluation of whether receiving sequential bilateral aTBS  
420 shows initial evidence of improving suicidal ideation in depressed  
421 adolescents.

#### 422 ***Recruitment***

423 Recruitment began April 4, 2022, after the protocol v2.0 was  
424 finalized and approved by the Data and Safety Monitoring Board (DSMB)  
425 November 10, 2021. The estimated completion date of the study is  
426 December 31, 2026. Adolescent participants are being recruited through the

427 Mayo Clinic Depression Center and Division of Child and Adolescent  
428 Psychiatry in Rochester, Minnesota. Recruitment is occurring through  
429 outpatient clinics, an 18-bed child and adolescent inpatient psychiatry unit,  
430 and Mayo Clinic Emergency Medicine Department in Rochester. Mayo  
431 Clinic Health System clinics throughout Minnesota and Wisconsin provide  
432 additional recruitment environments. Ongoing and future outreach efforts  
433 also involve local community and private treatment facilities in Rochester,  
434 St Paul, and Minneapolis in Minnesota. The PI (P.E.C.) has prior and  
435 planned collaborations with the Rochester Public School District, Rochester,  
436 Minnesota, including consultation with the school board. With appropriate  
437 approvals, recruitment flyers will be disseminated to the parents of all  
438 adolescents attending Rochester public schools.

439           During inpatient hospitalizations, outpatient visits, and emergency  
440 medicine department evaluations, a treatment team member will inform the  
441 research team and attending physician of a patient's potential interest. The  
442 attending physician will review the request and determine whether a  
443 discussion of research participation is appropriate. The PI or another  
444 research team member will be contacted to speak to the patient and family  
445 regarding participation. If the patient and family are interested, the research  
446 team will initiate the informed consent process.

447           The research team will discuss the study during staff meetings at  
448 internal clinical services and external facilities. External efforts will be  
449 tailored to foster community education regarding depression and suicidality  
450 in adolescents while establishing referral patterns. Flyers approved by the  
451 Mayo Clinic Institutional Review Board (IRB) will be posted in facilities to  
452 advertise the study. The research team will participate in local and national

453 events such as Suicide Awareness Day, National Depression Day, and  
454 National Mental Health Day to facilitate community engagement and  
455 participant recruitment. The PI will continue to access and collaborate with  
456 relevant offices in the Mayo Clinic Center for Clinical and Translational  
457 Science such as the Office of Community Engagement. These collaborations  
458 provide local speaking opportunities.

### 459 ***Randomization and Blinding***

460 Randomization will occur for each participant when that person  
461 meets all inclusion criteria, does not have any exclusions, and has  
462 satisfactorily completed all prestudy procedures. The study biostatistician  
463 (P.A.N.) generated a randomization schedule using a random number  
464 program on software (SAS via PROC PLAN, SAS Institute Inc).  
465 Participants will be randomly assigned in a 1:1 ratio to receive 1 of the 2  
466 treatment regimens (either 3 daily sequential bilateral aTBS sessions in the  
467 active arm or 3 daily sham sessions in the control arm) for 10 days.

468 The use of active and placebo (sham) coils facilitates blinding of  
469 the operator and participants receiving aTBS or sham treatments. A  
470 pretreatment and posttreatment expectancy and experience form will ask  
471 participants and parents to make a guess regarding their treatment arm  
472 (active or sham). Blinded study team members will also be asked to guess  
473 treatment assignments for each participant. The study team members  
474 completing clinical rating scales will not be allowed in the treatment suite  
475 during TBS treatment sessions and will be blinded to treatment assignment.

476 In the event of a device-related serious adverse effect, the PI will  
477 carefully assess whether breaking the blinding will critically affect how a  
478 participant is treated in response to the adverse effect and whether this

479 knowledge outweighs the implications to the scientific soundness of the  
480 study. This decision will be reviewed and approved by the study medical  
481 monitor. For most serious adverse effects, treatment would be discontinued,  
482 and symptoms would be treated regardless of the knowledge of whether the  
483 treatment received was active or sham.

#### 484 ***Data Collection and Management***

485           The primary acute outcome measure is the score on the C-SSRS  
486 of the 5-point severity of ideation subscale, with 1 indicating wish to be  
487 dead; 2, nonspecific active suicidal thoughts; 3, suicidal thoughts with any  
488 methods (no plan) without intent; 4, active suicidal ideation with some  
489 suicidal intent without a plan; and 5, active suicidal ideation with suicidal  
490 intent and a plan [68]. Another C-SSRS subscale that will be used is the  
491 intensity of ideation subscale (composed of frequency, duration,  
492 controllability, deterrents, and reasons for ideation) [68]. The C-SSRS has  
493 been validated for assessing suicidal ideation and behavior in adolescents  
494 and adults, with good predictive validity for death by suicide [68] (Table 2).  
495 The other study instruments are mentioned in the Participant Timeline  
496 section and Table 2.

497           Study retention is expected to be high for this study for multiple  
498 reasons. During the treatment phase of the study, participants will have  
499 frequent contact with the study team's child and adolescent psychiatrist (10  
500 daily visits). Both the participants and their parent or legal guardian will be  
501 told to contact their study doctor if the participant has any major mood or  
502 behavioral changes including suicidal ideation. Ongoing monitoring for  
503 worsening of depression and emergence of suicidal ideation and suicidal  
504 behaviors will be performed with the CDRS-R, C-SSRS, and Clinical Global

505 Impression-Severity Scale [68,77,82]. Additionally, the scheduling  
506 flexibility (including weekends) and the TBS dosing parameters (more  
507 tolerable treatment intensity) should be highly effective in retaining  
508 adolescent participants in this study. Nonadherence to the assigned treatment  
509 regimen is defined as missing 2 or more treatment days, or missing more  
510 than 20% of the total number of treatment sessions (ie, 6 sessions) occurring  
511 during the 2 weeks of treatment as outlined in the schedule of events.  
512 Outcomes data will be included in the analyses for any participant randomly  
513 assigned into the study who received at least 1 exposure (treatment) from the  
514 study device.

515           A CRF will be completed for each participant enrolled in the  
516 clinical study. The investigator-sponsor will review, approve, and sign and  
517 date each completed form to show responsibility for ensuring that all clinical  
518 data entered on the CRF are complete, accurate, and authentic. All study  
519 data will be managed as follows:

- 520       1. Data will be entered into a secure database (REDCap, Vanderbilt  
521       University).
- 522       2. Study data will be reviewed regularly by the PI and the Study  
523       Coordinator for the following:
  - 524           a. Inclusion criteria are met.
  - 525           b. Data are transcribed accurately and completely.
  - 526           c. Units of measure are recorded appropriately.
- 527       3. Details of the study treatments including treatment parameters, such  
528       as percentage MT for each treatment, will be stored in the device  
529       manufacturer's software (MagVenture Research Study System

- 530 software, MagVenture Inc). A daily summary of the treatments will be  
531 created and stored in the participant's source document.
- 532 4. Case files will be created for each participant where completed visit  
533 CRFs will be stored. Any AE-related CRFs will also be stored in the  
534 case file.
- 535 5. Nonelectronic source documents containing data will be stored in a  
536 locked cabinet in a secure office. Only authorized study staff will have  
537 access.
- 538 6. Electronic data will be stored in a secure database. Only authorized  
539 users will have access. All users will have unique identifiers and  
540 passwords. Sharing logon information is not permitted.

#### 541 ***Statistical Analysis***

542 All statistical analyses will be performed with SAS software  
543 version 9.4 (SAS Institute Inc). The level of significance will be set at  $\alpha=.05$   
544 (2-tailed). To address multiple testing where applicable, *P* values will be  
545 adjusted by using the false discovery rate [83].

546 Suicidal ideation (as measured by the score of the C-SSRS  
547 severity of ideation subscale) over the 10-day sequential bilateral aTBS trial  
548 period is the primary ordinal outcome measure (hypothesis 1a). The short-  
549 term change over time (10 days) in suicidal ideation will be compared  
550 between the 2 treatment groups (sequential bilateral aTBS vs sham  
551 stimulation) by using an ordinal logistic regression model within a  
552 generalized estimating equation (GEE) framework. The logistic model will  
553 contain fixed-effects terms for treatment, time, and treatment  $\times$  time  
554 interaction along with baseline C-SSRS severity of ideation subscale as a  
555 covariate. Age, sex, pubertal status, antidepressant medication status, and

556 depression severity (CDRS-R total as a time-varying covariate) will also be  
557 covariates in the model. Simple treatment group effects will also be assessed  
558 in each study period (10 days or 12 months). (See the sensitivity analysis  
559 section later for a missing not at random [MNAR] mechanism.)

560           After the treatment period ends, suicidal ideation will be assessed  
561 at monthly follow-up visits over a 12-month period (hypothesis 1b). An  
562 ordinal logistic regression model within a GEE analysis framework similar  
563 to that described for the primary outcome (hypothesis 1a) will be used to  
564 estimate suicidal ideation over the 12-month follow-up period. In addition to  
565 the covariates specified for the primary outcome, we will also consider  
566 including pharmacotherapy and psychotherapeutic intervention received  
567 over the follow-up period as additional covariates.

568           Emergency department visits and hospitalization visits related to  
569 suicidality will be assessed at monthly follow-up visits over the 12-month  
570 follow-up period (hypothesis 1c). A separate Poisson mixed-model analysis  
571 will be used to estimate the number of emergency department visits and the  
572 number of hospitalization visits for those who received sequential bilateral  
573 aTBS and for those who received sham stimulation. The model will contain  
574 fixed-effects terms for treatment, time, and treatment  $\times$  time interaction,  
575 with the same covariates identified earlier. Simple treatment group effects  
576 will also be assessed in each period. Maximum likelihood estimation, type 3  
577 tests of fixed effects, and generalized least-squares means will be used along  
578 with the best-fitting covariance structure. The sandwich (robust covariance  
579 matrix) estimator will also be considered. The Poisson model will be  
580 checked for overdispersion. The Poisson regression will model the logarithm  
581 of each outcome as a random variable, and the mean and variance will be



582 estimated on the logarithmic scale. Thus, to facilitate interpretation,  
583 geometric means will be reported, which will be obtained by exponentiating  
584 the log-scale parameter estimates. Generalized linear mixed-model  
585 procedures software (PROC GLIMMIX, SAS/STAT, SAS Institute Inc) will  
586 be used to conduct the Poisson regression for hypothesis 1c and provide a  
587 robust mechanism for handling data that are assumed missing at random.  
588 (See the sensitivity analysis section for data that are MNAR.) No subgroup  
589 analyses are planned.

590           An ordinal logistic regression model will be used to estimate  
591 severity of suicidal ideation at baseline from LIC1-100 measured with TMS-  
592 EMG before the intervention (hypothesis 2a). Age, sex, pubertal status,  
593 antidepressant medication status, and depression severity at baseline (CDRS-  
594 R total) will be covariates in the model. The maximum likelihood estimation  
595 and type 3 tests of fixed effects will be used along with the Wald  $\chi^2$  statistic.  
596 Robust standard errors (Huber sandwich estimator) will also be considered.  
597 For the ordinal logistic regression, the cumulative probabilities will be  
598 modeled over the lower-ordered suicidal ideation scale scores (less suicidal  
599 ideation). The adjusted ORs (odds of suicidal ideation from LIC1 with TMS-  
600 EMG) and 95% CI will be estimated as part of the model to interpret the  
601 relationship between the TMS-EMG biomarker and baseline suicidal  
602 ideation.

603           An ordinal logistic regression model within a GEE analysis  
604 framework similar to that described for hypothesis 1a will be used to  
605 examine the relationship between cortical inhibition (LIC1-100 measured  
606 with TMS-EMG as a time-varying covariate) and C-SSRS severity of  
607 ideation subscale (as the response variable) over the 10-day treatment trial

608 (hypothesis 2b). The parameter estimates (regression coefficients) will be  
609 interpreted from the solution for fixed effects in the GEE analysis. The  
610 adjusted OR (odds of suicidal ideation from cortical inhibition) and 95% CI  
611 will be estimated as part of the GEE model. The same covariates specified  
612 for hypothesis 1a will be in the model for hypothesis 2b.

613           An ordinal logistic regression model within a GEE analysis  
614 framework similar to that described earlier for hypothesis 2b will be used to  
615 examine the relationship between cortical inhibition (TMS-EEG markers  
616 N45 and N100) and C-SSRS severity of ideation subscale (as the response  
617 variable) over the 10-day treatment trial (hypothesis 3). A separate model  
618 will be implemented for each measure of TMS-EEG cortical inhibition. The  
619 same covariates specified for hypothesis 2b will be in the model for  
620 hypothesis 3. The parameter estimates (regression coefficients) will be  
621 interpreted from the solution for fixed effects in the GEE analysis. The  
622 adjusted OR (odds of suicidal ideation from TMS-EEG cortical inhibition)  
623 and 95% CI will be estimated as part of the GEE model.

#### 624 *Sensitivity Analysis to Handle Missing Data*

625           A sensitivity analysis is planned to address incomplete response  
626 patterns according to an MNAR mechanism. First, we will follow the  
627 outcome-based model of Diggle and Kenward [84] for longitudinal data with  
628 nonrandom missingness along with the model-based approach proposed by  
629 Carpenter et al [85] for modeling both the treatment response and the  
630 missing data process. These models are summarized here. If deemed  
631 necessary, we will build longitudinal models for the data, which include a  
632 model for the dropout (or missing data) process to assess the sensitivity of  
633 the results about the dependence between dropout (or missingness) and

634 treatment response. Additionally, if deemed necessary, we will consider  
635 implementing the semiparametric shared parameter model described by  
636 Tsonaka et al [86] to handle nonmonotone nonignorable missingness for  
637 mixed-effects models. A pattern-mixture model will also be considered if  
638 necessary. The results from such nonrandom dropout/missingness models  
639 will then be compared with the results from the proposed standard methods  
640 (dropout or missing at random models) to assess the sensitivity of the results  
641 to the effect of dropouts (or incomplete response patterns according to an  
642 MNAR mechanism).

### 643 ***Data Monitoring***

644 An National Institute of Mental Health (NIMH)-constituted  
645 DSMB is overseeing the study in accordance with the NIMH DSMB charter  
646 guidelines [87]. Clinical monitoring will be conducted by the NIMH Clinical  
647 Research Education, Support, and Training program. Goals of clinical site  
648 monitoring are to ensure that the rights and well-being of participants are  
649 protected; that the reported trial data are accurate, complete, and verifiable;  
650 and that the conduct of the trial complies with the approved protocol and any  
651 amendments, good clinical practice, and applicable regulatory requirements.  
652 Clinical monitoring includes reviewing the study database and documents  
653 including regulatory documents. Monitoring will be conducted throughout  
654 the study and involves targeted data verification of key data variables.  
655 Details of clinical site monitoring are documented in the clinical monitoring  
656 plan. This plan describes who will conduct the monitoring, at what  
657 frequency monitoring will be done, at what level of detail monitoring will be  
658 performed, and the distribution of monitoring reports. Copies of monitoring  
659 reports will be provided to the PI and to the NIMH DSMB liaison.

660                   An individualized quality management plan was developed to  
661 describe the clinical site’s quality management in addition to the site’s  
662 assurance and quality control measures already in place. The site staff will  
663 perform internal quality management of study conduct, data collection, and  
664 data documentation.

665 *Interim Analyses and Study-Stopping Rules*

666                   No interim analyses are planned. Study-stopping rules were  
667 developed in collaboration with the FDA and NIMH DSMB to ensure that  
668 participants are not exposed to risks across the study and that any potential  
669 risks are evaluated. These stopping rules apply to the 2-week period when  
670 participants are receiving the study intervention (active or sham sequential  
671 bilateral aTBS) but do not apply to the naturalistic 1-year follow-up portion  
672 of the study. No study-stopping rules were predetermined for events that  
673 take place during the follow-up period because suicide attempts and  
674 psychiatric hospitalizations are expected to be common events. AEs  
675 occurring during the follow-up period will be tracked. The study team will  
676 evaluate the expectedness and relatedness of these events; the IRB, DSMB,  
677 and FDA will provide oversight of these determinations. AEs and SAEs will  
678 be reported in the data reports and reviewed by the DSMB. The following  
679 study-stopping rules apply:

- 680                   • Two participants who experience a seizure.
- 681                   • One or more participants who experience status epilepticus.
- 682                   • One or more participants who attempt or die by suicide.
- 683                   • Two or more SAEs related to the study intervention and occurring  
684                   within the 2-week treatment period for 1 or more participants.

685                   If these study-stopping rules are met, enrollment of new  
686 participants will cease, but all study activities will continue for enrolled  
687 participants. The PI will consult with the DSMB and the FDA within 10  
688 business days of initial notice that study-stopping rules were met.

689 *AE Reporting and Harm*

690                   All AEs occurring during the study, including those not meeting  
691 the criteria of an unanticipated adverse device effect (UADE), will be  
692 recorded on the appropriate CRF. Expected clinical AEs and anticipated  
693 adverse device effects include pain or discomfort under the treatment coil;  
694 eye, facial, or skin pain; facial numbness or facial muscle twitching;  
695 toothache; blurred vision; seizures; cardiogenic syncope; sedation; and  
696 worsening mood symptoms. UADEs will be reported to the DSMB, FDA,  
697 and IRB immediately. Records of these events will be maintained, and  
698 reports will be submitted to the FDA and IRB according to the regulatory  
699 requirements. Expected clinical AEs and nonserious clinical AEs will be  
700 reported annually.

701                   The study follow-up period is defined as 12 months after the last  
702 administration of study treatment. All AEs occurring during the study  
703 treatment period will be recorded as required. All observed or volunteered  
704 adverse effects (serious or nonserious) and abnormal test findings will be  
705 recorded in the participant's case history regardless of the treatment group or  
706 a suspected causal relationship to the investigational device or, if applicable,  
707 to other study treatment or diagnostic products. For all adverse effects,  
708 sufficient information will be pursued and obtained regarding permit, an  
709 adequate determination of the outcome, and an assessment of the causal  
710 relationship between the adverse effect and the investigational device or

711 other study treatment or diagnostic product. The clinical course of each  
712 event will be followed up, as required, until resolution or stabilization or  
713 until the study treatment or participation is determined to not be the probable  
714 cause. SAEs that are still ongoing at the end of the study will be followed up  
715 to determine the final outcome. Any SAE that occurs after the study period  
716 and is considered to be at least possibly related to the study treatment or  
717 study participation will be recorded and reported immediately.

718           The sponsor-investigator will promptly review documented  
719 adverse effects and abnormal test findings to determine the following: 1)  
720 whether the abnormal test finding should be classified as an adverse effect;  
721 2) whether there is a reasonable possibility that the adverse effect was  
722 caused by the investigational device or other study treatments; and 3)  
723 whether the adverse effect meets the criteria for a serious adverse effect. If  
724 the sponsor-investigator’s final determination of causality is “unknown and  
725 of questionable relationship to the investigational device or other study  
726 treatments,” the adverse effect will be classified as associated with the use of  
727 the investigational device or other study treatments for reporting purposes. If  
728 the sponsor-investigator’s final determination of causality is “unknown but  
729 not related to the investigational device or other study treatments,” this  
730 determination and the rationale for the determination will be documented in  
731 the respective participant’s case history.

732           The sponsor-investigator will promptly review documented  
733 UADEs (FDA Form 3500A) and will report the results from the evaluation  
734 to the FDA and DSMB within 10 workdays and to the Mayo Clinic IRB  
735 within 5 workdays of initial notice of the effect. Thereafter, the sponsor-

736 investigator will submit additional reports concerning the effect as  
737 requested.

738           The sponsor-investigator will permit study-related monitoring,  
739 audits, and inspections by the IRB, the monitors, and government regulatory  
740 agencies of all study-related documents (eg, source documents, regulatory  
741 documents, data collection instruments, study data). The sponsor-  
742 investigator will ensure the capability for inspections of applicable study-  
743 related facilities (eg, pharmacy, diagnostic laboratory). Participation as a  
744 sponsor-investigator in this study implies acceptance of potential inspection  
745 by government regulatory authorities and applicable compliance offices.

#### 746 ***Ethics and Dissemination***

##### 747 *Informed Consent*

748           Prospective participants will be assured that participation is  
749 voluntary. All participants for this study will receive a consent/assent form  
750 describing this study and providing sufficient information for participants  
751 and their parents or legal guardian to make an informed decision about  
752 whether to participate. Formal consent must be obtained by using the  
753 approved IRB consent form before a participant undergoes any study  
754 procedure. The consent form must be signed and dated by the participant or  
755 the participant's legally authorized representative, and by the study team  
756 member obtaining the informed consent.

##### 757 *Confidentiality*

758           Information including clinical information about study  
759 participants will be kept confidential and managed according to the  
760 requirements of the Health Insurance Portability and Accountability Act of  
761 1996 (HIPAA). Those regulations require a signed authorization by each

762 study participant informing the participant of the following: what protected  
763 health information (PHI) [12] will be collected from participants, who will  
764 have access to that information and why, who will use or disclose that  
765 information, and the rights of a participant to revoke their authorization to  
766 use their PHI. If a participant revokes authorization to collect or use PHI, the  
767 investigator, by regulation, retains the ability to use all information collected  
768 before the revocation of participant authorization. For participants who have  
769 revoked authorization to collect or use PHI, attempts will be made to obtain  
770 permission to collect at least vital status (long-term survival status that the  
771 participant is alive) at the end of the originally scheduled study period.

772           Participant confidentiality and privacy are strictly held in trust by  
773 the participating investigators, their staff, and the sponsor. Therefore, the  
774 study documentation, data, and all other information generated will be held  
775 in strict confidence. No information concerning either the study or the data  
776 will be released to any unauthorized third party without prior written  
777 approval of the sponsor. All research activities will be conducted in as  
778 private a setting as possible. Potential participants will have the opportunity  
779 to discuss study participation without their parent or guardian present. The  
780 study monitor, other authorized representatives of the sponsor, and  
781 representatives of the NIH, the FDA, and the Mayo Clinic IRB may inspect  
782 all documents and records required to be maintained by the investigator,  
783 including but not limited to medical records. Study participants' contact  
784 information will be securely stored for internal use during the study. At the  
785 end of the study, all records will continue to be kept in a secure location for  
786 as long as dictated by the reviewing IRB, institutional policies, FDA



787 investigational device exemption (IDE) record requirements, and sponsor  
788 requirements. We are not planning to collect biological specimens.

789           To further protect the privacy of study participants, the NIH will  
790 issue a Certificate of Confidentiality. This certificate protects identifiable  
791 research information from forced disclosure. It allows the investigator and  
792 others who have access to research records to refuse to disclose identifying  
793 information on research participation in any civil, criminal, administrative,  
794 legislative, or other proceeding, whether at the federal, state, or local level.  
795 By protecting researchers and institutions from being compelled to disclose  
796 information that would identify research participants, Certificates of  
797 Confidentiality help achieve the research objectives and promote  
798 participation in studies by helping assure confidentiality and privacy to  
799 participants.

#### 800 *Dissemination*

801           The PI/sponsor holds the primary responsibility for publications  
802 of results from the proposed study. The PI/sponsor and study team will  
803 present findings at national and international conferences and will publish  
804 findings in peer-reviewed journals. Results will be posted to  
805 ClinicalTrials.gov within 12 months of final data collection for the primary  
806 outcomes.

#### 807 **Discussion**

808           This is the first known randomized controlled trial to examine  
809 sequential bilateral aTBS in depressed adolescents with suicidal ideation.  
810 The study addresses 2 NIMH Strategic Research Strategies: 3.2, “Develop  
811 ways to tailor existing and new interventions to optimize outcomes,” and  
812 3.3, “Test interventions for effectiveness in community practice settings”

813 [88,89]. If this aTBS treatment protocol and the proposed panel of  
814 biomarkers are shown to be safe and effective, they can be rapidly  
815 implemented into clinical practice. This novel approach may facilitate a  
816 critical paradigm shift toward brain-based approaches for assessing and  
817 treating suicidal ideation in adolescents with MDD.

### 818 **Supplementary Information**

819 The online version contains supplementary material (Appendix 1.  
820 Standard Protocol Items: Recommendations for Interventional Trials  
821 [SPIRIT] 2013 Checklist [additional file 1.doc]; Appendix 2. Study  
822 Administrative Information [additional file 2.doc]. Appendix 3. Sample  
823 Consent Forms [additional file 3.pdf and additional file 4.pdf] [Used with  
824 permission of Mayo Foundation for Medical Education and Research.].

### 825 ***Declarations***

#### 826 *Ethics Approval and Consent to Participate*

827 This study is to be conducted according to US government  
828 regulations and institutional research policies and procedures. This protocol  
829 was submitted, and any amendments will be submitted, to a properly  
830 constituted local institutional review board (IRB), the Mayo Clinic IRB, in  
831 agreement with local legal prescriptions, for formal approval of the study.  
832 The IRB approved this study (#20-009630). All participants or their parents  
833 or legal guardian will be asked to sign an informed consent form as  
834 described in the article.

#### 835 *Consent for Publication*

836 Not applicable.

837 *Availability of Data*

838           Because the study is funded by the National Institute of Mental  
839 Health (NIMH), data sharing through the NIMH Data Archive (NDA) is  
840 required. The NDA is a large database in which deidentified study data from  
841 many NIMH studies are stored and managed. Any researcher who requests  
842 access to the deidentified data of the NDA is bound to adhere to strict data  
843 safety practices and to avoid any attempts at deidentification. The  
844 investigators' intention to submit deidentified participant data to the NDA is  
845 stated in the consent and assent documents, and participants or guardians are  
846 able to opt out of this data sharing at any time. Opting out of NDA data  
847 sharing does not in any way affect trial eligibility.

848 *Competing Interests*

849           Dr Croarkin has received research grant support from Neuronetics  
850 Inc, NeoSync Inc, and Pfizer Inc. He has received in-kind support  
851 (equipment, supplies, and genotyping) for research studies from Assurex  
852 Health Inc, Neuronetics Inc, and MagVenture Inc. He has consulted for  
853 Engrail Therapeutics Inc, Myriad Neuroscience, Procter & Gamble, and  
854 Sunovion. Dr Vande Voort has received in-kind support (supplies and  
855 genotyping) from Assurex Health Inc. The other authors declare that they  
856 have no competing interests.

857 *Funding*

858           This project is supported by Grant Number 1 R01 MH124655-01  
859 from the NIMH, National Institutes of Health (NIH), and by Grant Number  
860 UL1 TR000135 from the National Center for Advancing Translational  
861 Sciences (NCATS). The content of this protocol and publication is solely the

862 responsibility of the authors and does not necessarily represent the official  
863 views of the NIH.

864 *Authors' Contributions*

865 P.E.C. is the principal investigator, conceived the study concept,  
866 and spearheaded protocol development. P.A.N., M.J.Z., J.L.V., J.M.L., J.S.,  
867 and P.E.C. designed the study aims, hypotheses, and statistical analyses.  
868 D.Y., C.O., and J.F.G. drafted the protocol, provided additional intellectual  
869 input, and made substantial revisions. All authors read and approved the  
870 final manuscript.

871 *Authors' Information*

872 See title page.

873

874

## References

- 875 1. Fazel S, Runeson B. Suicide. *N Engl J Med*. 2020;382(3):266-74.
- 876 2. Kann L, McManus T, Harris WA, Shanklin SL, Flint KH, Queen B, et  
877 al. Youth Risk Behavior Surveillance - United States, 2017. *MMWR*  
878 *Surveill Summ*. 2018;67(8):1-114.
- 879 3. World Health Organization. Preventing suicide: a global imperative.  
880 Geneva: World Health Organization; 2014. Available from:  
881 <https://www.who.int/publications/i/item/9789241564779>.
- 882 4. Miron O, Yu KH, Wilf-Miron R, Kohane IS. Suicide Rates Among  
883 Adolescents and Young Adults in the United States, 2000-2017.  
884 *JAMA*. 2019;321(23):2362-4.
- 885 5. Olfson M, Blanco C, Wall M, Liu SM, Saha TD, Pickering RP, et al.  
886 National Trends in Suicide Attempts Among Adults in the United  
887 States. *JAMA Psychiatry*. 2017;74(11):1095-103.
- 888 6. Copeland WE, Goldston DB, Costello EJ. Adult Associations of  
889 Childhood Suicidal Thoughts and Behaviors: A Prospective,  
890 Longitudinal Analysis. *J Am Acad Child Adolesc Psychiatry*.  
891 2017;56(11):958-65 e4.
- 892 7. Brent DA, Greenhill LL, Compton S, Emslie G, Wells K, Walkup JT,  
893 et al. The Treatment of Adolescent Suicide Attempters study (TASA):  
894 predictors of suicidal events in an open treatment trial. *J Am Acad*  
895 *Child Adolesc Psychiatry*. 2009;48(10):987-96.
- 896 8. Zalsman G, Hawton K, Wasserman D, van Heeringen K, Arensman E,  
897 Sarchiapone M, et al. Suicide prevention strategies revisited: 10-year  
898 systematic review. *Lancet Psychiatry*. 2016;3(7):646-59.

- 899 9. Bennett K, Rhodes AE, Duda S, Cheung AH, Manassis K, Links P, et  
900 al. A Youth Suicide Prevention Plan for Canada: A Systematic  
901 Review of Reviews. *Can J Psychiatry*. 2015;60(6):245-57.
- 902 10. Franklin JC, Ribeiro JD, Fox KR, Bentley KH, Kleiman EM, Huang  
903 X, et al. Risk factors for suicidal thoughts and behaviors: A meta-  
904 analysis of 50 years of research. *Psychol Bull*. 2017;143(2):187-232.
- 905 11. Gordon JA, Frost Bellgowan JA, Lawhorn C, Scheinert RB.  
906 Challenges and Opportunities in Psychiatric Neuroscience. *Cold  
907 Spring Harb Symp Quant Biol*. 2018;83:1-8.
- 908 12. Kapur S, Phillips AG, Insel TR. Why has it taken so long for  
909 biological psychiatry to develop clinical tests and what to do about it?  
910 *Mol Psychiatry*. 2012;17(12):1174-9.
- 911 13. Perlis RH. Translating biomarkers to clinical practice. *Mol Psychiatry*.  
912 2011;16(11):1076-87.
- 913 14. Croarkin PE, Nakonezny PA, Deng ZD, Romanowicz M, Voort JLV,  
914 Camsari DD, et al. High-frequency repetitive TMS for suicidal  
915 ideation in adolescents with depression. *J Affect Disord*.  
916 2018;239:282-90.
- 917 15. Bastiampillai T, Sharfstein SS, Allison S. Increasing the Use of  
918 Lithium and Clozapine in US Suicide Prevention. *JAMA Psychiatry*.  
919 2017;74(4):423.
- 920 16. Daskalakis ZJ, Farzan F, Barr MS, Rusjan PM, Favalli G, Levinson  
921 AJ, et al. Evaluating the relationship between long interval cortical  
922 inhibition, working memory and gamma band activity in the  
923 dorsolateral prefrontal cortex. *Clin EEG Neurosci*. 2008;39(3):150-5.

- 924 17. Croarkin PE, Levinson AJ, Daskalakis ZJ. Evidence for GABAergic  
925 inhibitory deficits in major depressive disorder. *Neurosci Biobehav*  
926 *Rev.* 2011;35(3):818-25.
- 927 18. Krnjevic K. Glutamate and gamma-aminobutyric acid in brain.  
928 *Nature.* 1970;228(5267):119-24.
- 929 19. Schmaal L, van Harmelen AL, Chatzi V, Lippard ETC, Toenders YJ,  
930 Averill LA, et al. Imaging suicidal thoughts and behaviors: a  
931 comprehensive review of 2 decades of neuroimaging studies. *Mol*  
932 *Psychiatry.* 2020;25(2):408-27.
- 933 20. Chang BP, Franklin JC, Ribeiro JD, Fox KR, Bentley KH, Kleiman  
934 EM, et al. Biological risk factors for suicidal behaviors: a meta-  
935 analysis. *Transl Psychiatry.* 2016;6(9):e887.
- 936 21. Oquendo MA, Sullivan GM, Sudol K, Baca-Garcia E, Stanley BH,  
937 Sublette ME, et al. Toward a biosignature for suicide. *Am J*  
938 *Psychiatry.* 2014;171(12):1259-77.
- 939 22. Gabbay V, Bradley KA, Mao X, Ostrover R, Kang G, Shungu DC.  
940 Anterior cingulate cortex gamma-aminobutyric acid deficits in youth  
941 with depression. *Transl Psychiatry.* 2017;7(8):e1216.
- 942 23. Gabbay V, Mao X, Klein RG, Ely BA, Babb JS, Panzer AM, et al.  
943 Anterior cingulate cortex gamma-aminobutyric acid in depressed  
944 adolescents: relationship to anhedonia. *Arch Gen Psychiatry.*  
945 2012;69(2):139-49.
- 946 24. Lewis CP, Nakonezny PA, Ameis SH, Vande Voort JL, Husain MM,  
947 Emslie GJ, et al. Cortical inhibitory and excitatory correlates of  
948 depression severity in children and adolescents. *J Affect Disord.*  
949 2016;190:566-75.

- 950 25. Lewis CP, Nakonezny PA, Blacker CJ, Vande Voort JL, Port JD,  
951 Worrell GA, et al. Cortical inhibitory markers of lifetime suicidal  
952 behavior in depressed adolescents. *Neuropsychopharmacology*.  
953 2018;43(9):1822-31.
- 954 26. King JD, Horton SE, Hughes JL, Eaddy M, Kennard BD, Emslie GJ,  
955 et al. The Interpersonal-Psychological Theory of Suicide in  
956 Adolescents: A Preliminary Report of Changes Following Treatment.  
957 *Suicide Life Threat Behav*. 2018;48(3):294-304.
- 958 27. Kotak VC, Mirallave A, Mowery TM, Sanes DH. GABAergic  
959 inhibition gates excitatory LTP in perirhinal cortex. *Hippocampus*.  
960 2017;27(12):1217-23.
- 961 28. Levitt JG, Kalender G, O'Neill J, Diaz JP, Cook IA, Ginder N, et al.  
962 Dorsolateral prefrontal gamma-aminobutyric acid in patients with  
963 treatment-resistant depression after transcranial magnetic stimulation  
964 measured with magnetic resonance spectroscopy. *J Psychiatry*  
965 *Neurosci*. 2019;44(6):386-94.
- 966 29. Li CT, Huang YZ, Bai YM, Tsai SJ, Su TP, Cheng CM. Critical role  
967 of glutamatergic and GABAergic neurotransmission in the central  
968 mechanisms of theta-burst stimulation. *Hum Brain Mapp*.  
969 2019;40(6):2001-9.
- 970 30. George MS, Raman R, Benedek DM, Pelic CG, Grammer GG, Stokes  
971 KT, et al. A two-site pilot randomized 3 day trial of high dose left  
972 prefrontal repetitive transcranial magnetic stimulation (rTMS) for  
973 suicidal inpatients. *Brain Stimul*. 2014;7(3):421-31.
- 974 31. Weissman CR, Blumberger DM, Brown PE, Isserles M, Rajji TK,  
975 Downar J, et al. Bilateral Repetitive Transcranial Magnetic



- 976 Stimulation Decreases Suicidal Ideation in Depression. *J Clin*  
977 *Psychiatry*. 2018;79(3).
- 978 32. Stagg CJ, Wylezinska M, Matthews PM, Johansen-Berg H, Jezzard P,  
979 Rothwell JC, et al. Neurochemical effects of theta burst stimulation as  
980 assessed by magnetic resonance spectroscopy. *J Neurophysiol*.  
981 2009;101(6):2872-7.
- 982 33. McClintock SM, Reti IM, Carpenter LL, McDonald WM, Dubin M,  
983 Taylor SF, et al. Consensus Recommendations for the Clinical  
984 Application of Repetitive Transcranial Magnetic Stimulation (rTMS)  
985 in the Treatment of Depression. *J Clin Psychiatry*. 2018;79(1).
- 986 34. Perera T, George MS, Grammer G, Janicak PG, Pascual-Leone A,  
987 Wirecki TS. The Clinical TMS Society Consensus Review and  
988 Treatment Recommendations for TMS Therapy for Major Depressive  
989 Disorder. *Brain Stimul*. 2016;9(3):336-46.
- 990 35. Blumberger DM, Vila-Rodriguez F, Thorpe KE, Feffer K, Noda Y,  
991 Giacobbe P, et al. Effectiveness of theta burst versus high-frequency  
992 repetitive transcranial magnetic stimulation in patients with  
993 depression (THREE-D): a randomised non-inferiority trial. *Lancet*.  
994 2018;391(10131):1683-92.
- 995 36. Fitzgerald PB, Chen L, Richardson K, Daskalakis ZJ, Hoy KE. A pilot  
996 investigation of an intensive theta burst stimulation protocol for  
997 patients with treatment resistant depression. *Brain Stimul*.  
998 2020;13(1):137-44.
- 999 37. Huang YZ, Edwards MJ, Rounis E, Bhatia KP, Rothwell JC. Theta  
1000 burst stimulation of the human motor cortex. *Neuron*. 2005;45(2):201-  
1001 6.

- 1002 38. Mott MC, Gordon JA, Koroshetz WJ. The NIH BRAIN Initiative:  
1003 Advancing neurotechnologies, integrating disciplines. *PLoS Biol.*  
1004 2018;16(11):e3000066.
- 1005 39. Seewoo BJ, Hennessy LA, Feindel KW, Etherington SJ, Croarkin PE,  
1006 Rodger J. Validation of Chronic Restraint Stress Model in Young  
1007 Adult Rats for the Study of Depression Using Longitudinal  
1008 Multimodal MR Imaging. *eNeuro.* 2020;7(4).
- 1009 40. Williams NR, Sudheimer KD, Bentzley BS, Pannu J, Stimpson KH,  
1010 Duvio D, et al. High-dose spaced theta-burst TMS as a rapid-acting  
1011 antidepressant in highly refractory depression. *Brain.*  
1012 2018;141(3):e18.
- 1013 41. Dhami P, Knyahnytska Y, Atluri S, Lee J, Courtney DB, Croarkin PE,  
1014 et al. Feasibility and clinical effects of theta burst stimulation in youth  
1015 with major depressive disorders: An open-label trial. *J Affect Disord.*  
1016 2019;258:66-73.
- 1017 42. Hong YH, Wu SW, Pedapati EV, Horn PS, Huddleston DA, Laue CS,  
1018 et al. Safety and tolerability of theta burst stimulation vs. single and  
1019 paired pulse transcranial magnetic stimulation: a comparative study of  
1020 165 pediatric subjects. *Front Hum Neurosci.* 2015;9:29.
- 1021 43. Chung SW, Lewis BP, Rogasch NC, Saeki T, Thomson RH, Hoy KE,  
1022 et al. Demonstration of short-term plasticity in the dorsolateral  
1023 prefrontal cortex with theta burst stimulation: A TMS-EEG study.  
1024 *Clin Neurophysiol.* 2017;128(7):1117-26.
- 1025 44. Gong N, Li Y, Cai GQ, Niu RF, Fang Q, Wu K, et al. GABA  
1026 transporter-1 activity modulates hippocampal theta oscillation and

- 1027 theta burst stimulation-induced long-term potentiation. *J Neurosci.*  
1028 2009;29(50):15836-45.
- 1029 45. Feng YW, Huang YQ, Yan Y, Li G, He XF, Liang FY, et al. Phasic  
1030 GABA signaling mediates the protective effects of cTBS against  
1031 cerebral ischemia in mice. *Neurosci Lett.* 2020;715:134611.
- 1032 46. Li CT, Chen MH, Juan CH, Huang HH, Chen LF, Hsieh JC, et al.  
1033 Efficacy of prefrontal theta-burst stimulation in refractory depression:  
1034 a randomized sham-controlled study. *Brain.* 2014;137(Pt 7):2088-98.
- 1035 47. Kimbrell TA, Little JT, Dunn RT, Frye MA, Greenberg BD,  
1036 Wassermann EM, et al. Frequency dependence of antidepressant  
1037 response to left prefrontal repetitive transcranial magnetic stimulation  
1038 (rTMS) as a function of baseline cerebral glucose metabolism. *Biol*  
1039 *Psychiatry.* 1999;46(12):1603-13.
- 1040 48. Teneback CC, Nahas Z, Speer AM, Molloy M, Stallings LE, Spicer  
1041 KM, et al. Changes in prefrontal cortex and paralimbic activity in  
1042 depression following two weeks of daily left prefrontal TMS. *J*  
1043 *Neuropsychiatry Clin Neurosci.* 1999;11(4):426-35.
- 1044 49. Sonmez AI, Camsari DD, Nandakumar AL, Voort JLV, Kung S,  
1045 Lewis CP, et al. Accelerated TMS for Depression: A systematic  
1046 review and meta-analysis. *Psychiatry Res.* 2019;273:770-81.
- 1047 50. Abujadi C, Croarkin PE, Bellini BB, Brentani H, Marcolin MA.  
1048 Intermittent theta-burst transcranial magnetic stimulation for autism  
1049 spectrum disorder: an open-label pilot study. *Braz J Psychiatry.*  
1050 2018;40(3):309-11.
- 1051 51. Croarkin PE, Nakonezny PA, Husain MM, Melton T, Buyukdura JS,  
1052 Kennard BD, et al. Evidence for increased glutamatergic cortical

- 1053 facilitation in children and adolescents with major depressive  
1054 disorder. *JAMA Psychiatry*. 2013;70(3):291-9.
- 1055 52. Levinson AJ, Fitzgerald PB, Favalli G, Blumberger DM, Daigle M,  
1056 Daskalakis ZJ. Evidence of cortical inhibitory deficits in major  
1057 depressive disorder. *Biol Psychiatry*. 2010;67(5):458-64.
- 1058 53. Ziemann U, Reis J, Schwenkreis P, Rosanova M, Strafella A, Badawy  
1059 R, et al. TMS and drugs revisited 2014. *Clin Neurophysiol*.  
1060 2015;126(10):1847-68.
- 1061 54. Ziemann U. Pharmacology of TMS. *Suppl Clin Neurophysiol*.  
1062 2003;56:226-31.
- 1063 55. Ziemann U. TMS and drugs. *Clin Neurophysiol*. 2004;115(8):1717-  
1064 29.
- 1065 56. Belardinelli P, Biabani M, Blumberger DM, Bortoletto M, Casarotto  
1066 S, David O, et al. Reproducibility in TMS-EEG studies: A call for  
1067 data sharing, standard procedures and effective experimental control.  
1068 *Brain Stimul*. 2019;12(3):787-90.
- 1069 57. Conde V, Tomasevic L, Akopian I, Stanek K, Saturnino GB,  
1070 Thielscher A, et al. The non-transcranial TMS-evoked potential is an  
1071 inherent source of ambiguity in TMS-EEG studies. *Neuroimage*.  
1072 2019;185:300-12.
- 1073 58. Siebner HR, Conde V, Tomasevic L, Thielscher A, Bergmann TO.  
1074 Distilling the essence of TMS-evoked EEG potentials (TEPs): A call  
1075 for securing mechanistic specificity and experimental rigor. *Brain*  
1076 *Stimul*. 2019;12(4):1051-4.

- 1077 59. Tremblay S, Rogasch NC, Premoli I, Blumberger DM, Casarotto S,  
1078 Chen R, et al. Clinical utility and prospective of TMS-EEG. Clin  
1079 Neurophysiol. 2019;130(5):802-44.
- 1080 60. Voineskos D, Blumberger DM, Zomorodi R, Rogasch NC, Farzan F,  
1081 Foussias G, et al. Altered Transcranial Magnetic Stimulation-  
1082 Electroencephalographic Markers of Inhibition and Excitation in the  
1083 Dorsolateral Prefrontal Cortex in Major Depressive Disorder. Biol  
1084 Psychiatry. 2019;85(6):477-86.
- 1085 61. Croarkin PE, Rotenberg A. Pediatric Neuromodulation Comes of Age.  
1086 J Child Adolesc Psychopharmacol. 2016;26(7):578-81.
- 1087 62. Croarkin PE, Nakonezny PA, Husain MM, Port JD, Melton T,  
1088 Kennard BD, et al. Evidence for pretreatment LIC1 deficits among  
1089 depressed children and adolescents with nonresponse to fluoxetine.  
1090 Brain Stimul. 2014;7(2):243-51.
- 1091 63. Doruk Camsari D, Lewis CP, Sonmez AI, Nandakumar AL,  
1092 Gresbrink MA, Daskalakis ZJ, et al. Transcranial Magnetic  
1093 Stimulation Markers of Antidepressant Treatment in Adolescents  
1094 With Major Depressive Disorder. Int J Neuropsychopharmacol.  
1095 2019;22(7):435-44.
- 1096 64. Lewis CP, Camsari DD, Sonmez AI, Nandakumar AL, Gresbrink  
1097 MA, Daskalakis ZJ, et al. Preliminary evidence of an association  
1098 between increased cortical inhibition and reduced suicidal ideation in  
1099 adolescents treated for major depression. J Affect Disord.  
1100 2019;244:21-4.

- 1101 65. Grabb MC, Gobburu JVS. Challenges in developing drugs for  
1102 pediatric CNS disorders: A focus on psychopharmacology. *Prog*  
1103 *Neurobiol.* 2017;152:38-57.
- 1104 66. Kennard B, Mayes T, King J, Moorehead A, Wolfe K, Hughes J, et al.  
1105 The Development and Feasibility Outcomes of a Youth Suicide  
1106 Prevention Intensive Outpatient Program. *J Adolesc Health.*  
1107 2019;64(3):362-9.
- 1108 67. Kennard BD, Silva SG, Mayes TL, Rohde P, Hughes JL, Vitiello B, et  
1109 al. Assessment of safety and long-term outcomes of initial treatment  
1110 with placebo in TADS. *Am J Psychiatry.* 2009;166(3):337-44.
- 1111 68. Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo  
1112 MA, et al. The Columbia-Suicide Severity Rating Scale: initial  
1113 validity and internal consistency findings from three multisite studies  
1114 with adolescents and adults. *Am J Psychiatry.* 2011;168(12):1266-77.
- 1115 69. Keel JC, Smith MJ, Wassermann EM. A safety screening  
1116 questionnaire for transcranial magnetic stimulation. *Clin*  
1117 *Neurophysiol.* 2001;112(4):720.
- 1118 70. Sackeim HA. The definition and meaning of treatment-resistant  
1119 depression. *J Clin Psychiatry.* 2001;62 Suppl 16:10-7.
- 1120 71. Carskadon MA, Acebo C. A self-administered rating scale for  
1121 pubertal development. *J Adolesc Health.* 1993;14(3):190-5.
- 1122 72. Sheehan DV, Sheehan KH, Shytle RD, Janavs J, Bannon Y, Rogers  
1123 JE, et al. Reliability and validity of the Mini International  
1124 Neuropsychiatric Interview for Children and Adolescents (MINI-  
1125 KID). *J Clin Psychiatry.* 2010;71(3):313-26.

- 1126 73. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller  
1127 E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.):  
1128 the development and validation of a structured diagnostic psychiatric  
1129 interview for DSM-IV and ICD-10. *J Clin Psychiatry*. 1998;59 Suppl  
1130 20:22-33;quiz 4-57.
- 1131 74. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for  
1132 mania: reliability, validity and sensitivity. *Br J Psychiatry*.  
1133 1978;133:429-35.
- 1134 75. Poznanski EO, Cook SC, Carroll BJ. A depression rating scale for  
1135 children. *Pediatrics*. 1979;64(4):442-50.
- 1136 76. Beck AT, Steer RA, Brown GK. Manual for the Beck Depression  
1137 Inventory-II. San Antonio (TX): Psychological Corporation; 1996.
- 1138 77. Guy W, National Institute of Mental Health (U.S.).  
1139 Psychopharmacology Research Branch., Early Clinical Drug  
1140 Evaluation Program. Clinical Global Impressions. ECDEU  
1141 assessment manual for psychopharmacology. Rev. ed. Rockville, Md.:  
1142 U.S. Dept. of Health Education and Welfare Public Health Service  
1143 Alcohol Drug Abuse and Mental Health Administration National  
1144 Institute of Mental Health Psychopharmacology Research Branch  
1145 Division of Extramural Research Programs; 1976. p. 218-22.
- 1146 78. Hodes RJ, Insel TR, Landis SC, Research NIHBfN. The NIH toolbox:  
1147 setting a standard for biomedical research. *Neurology*. 2013;80(11  
1148 Suppl 3):S1.
- 1149 79. Beam W, Borckardt JJ, Reeves ST, George MS. An efficient and  
1150 accurate new method for locating the F3 position for prefrontal TMS  
1151 applications. *Brain Stimul*. 2009;2(1):50-4.

- 1152 80. Wall CA, Croarkin PE, Maroney-Smith MJ, Haugen LM, Baruth JM,  
1153 Frye MA, et al. Magnetic Resonance Imaging-Guided, Open-Label,  
1154 High-Frequency Repetitive Transcranial Magnetic Stimulation for  
1155 Adolescents with Major Depressive Disorder. *J Child Adolesc*  
1156 *Psychopharmacol.* 2016;26(7):582-9.
- 1157 81. Wall CA, Croarkin PE, Sim LA, Husain MM, Janicak PG, Kozel FA,  
1158 et al. Adjunctive use of repetitive transcranial magnetic stimulation in  
1159 depressed adolescents: a prospective, open pilot study. *J Clin*  
1160 *Psychiatry.* 2011;72(9):1263-9.
- 1161 82. Poznanski EO, Grossman JA, Buchsbaum Y, Banegas M, Freeman L,  
1162 Gibbons R. Preliminary studies of the reliability and validity of the  
1163 children's depression rating scale. *J Am Acad Child Psychiatry.*  
1164 1984;23(2):191-7.
- 1165 83. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A  
1166 Practical and Powerful Approach to Multiple Testing. *Journal of the*  
1167 *Royal Statistical Society: Series B (Methodological).* 1995;57(1):289-  
1168 300.
- 1169 84. Diggle P, Kenward MG. Informative Drop-Out in Longitudinal Data  
1170 Analysis. *Journal of the Royal Statistical Society Series C (Applied*  
1171 *Statistics).* 1994;43(1):49-93.
- 1172 85. Carpenter J, Pocock S, Lamm CJ. Coping with missing data in clinical  
1173 trials: a model-based approach applied to asthma trials. *Stat Med.*  
1174 2002;21(8):1043-66.
- 1175 86. Tsonaka R, Verbeke G, Lesaffre E. A Semi-Parametric Shared  
1176 Parameter Model to Handle Nonmonotone Nonignorable Missingness.  
1177 *Biometrics.* 2009;65(1):81-7.



- 1178 87. National Institute of Mental Health, National Institutes of Health, US  
1179 Department of Health and Human Services. NIMH Policy Governing  
1180 the Monitoring of Clinical Trials Bethesda (MD): National Institute of  
1181 Mental Health; 2015 [Available from:  
1182 [https://www.nimh.nih.gov/funding/clinical-research/nimh-policy-](https://www.nimh.nih.gov/funding/clinical-research/nimh-policy-governing-the-monitoring-of-clinical-trials)  
1183 [governing-the-monitoring-of-clinical-trials](https://www.nimh.nih.gov/funding/clinical-research/nimh-policy-governing-the-monitoring-of-clinical-trials).  
1184 88. Insel TR. The NIMH experimental medicine initiative. World  
1185 Psychiatry. 2015;14(2):151-3.  
1186 89. National Institute of Mental Health. Strategic Plan Goals 2022  
1187 [Available from: [https://www.nimh.nih.gov/about/strategic-planning-](https://www.nimh.nih.gov/about/strategic-planning-reports)  
1188 [reports](https://www.nimh.nih.gov/about/strategic-planning-reports).





Case report forms	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Adverse events	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Serious adverse events	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Concurrent psychotherapy	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Concurrent medications	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Hospitalizations related to suicidality noted														X
Emergency department visits related to suicidality noted														X

91 Abbreviations: aTBS, accelerated theta burst stimulation; ATHF, Antidepressant Treatment History Form; NIH, National Institutes of Health; t, timepoint; TASS, Transcranial  
92 Magnetic Stimulation Safety Screen; TMS-EEG, transcranial magnetic stimulation and electroencephalography; TMS-EMG, transcranial magnetic stimulation and electromyography;  
93 X, occurs at that time.  
94 <sup>a</sup> If symptoms of mania occur.  
95

96

1197

**Table 2.** Description of Assessments

<b>Assessment</b>	<b>Description</b>
Antidepressant Treatment History Form (ATHF)	Systematic documentation of prior psychotropic medication exposure and to quantify treatment resistance (No. of failed antidepressant trials with an adequate dose and duration)
Auditory thresholds	Audiometry testing
Beck Depression Inventory-II (BDI-II)	Validated, 21-item, self-report measure with a score range of 0-63
Brief Affective Neuroscience Personality Scale	Validated 33-item, self-report measure collected to assess behavioral characteristics in 6 affective neurobiological systems (play, seek, care, fear, anger, sadness)
Children's Depression Rating Scale Revised (CDRS-R)	Validated, 17-item, clinician-rated tool to assess severity of depression, with total possible scores ranging from 17 to 113; parents provide input into 14 of the items
Clinical Global Impressions– Severity Scale (CGI-S)	A standard measure of symptom severity and treatment response
Columbia–Suicide Severity Rating Scale (C-SSRS)	Validated, clinician-rated tool collected to assess lifetime and ongoing suicidal ideation and behavior; scale's severity of ideation subscale is a 5-point ordinal scale that is the primary clinical outcome measure for this study

Mini-International Neuropsychiatric Interview for Children and Adolescents (MINI-KID) and Mini-International Neuropsychiatric Interview (MINI)	Structured psychiatric interview (MINI-KID for ages 12-17 y and MINI for $\geq 18$ y) done to confirm diagnostic inclusion criteria and to rule out diagnostic exclusion criteria
NIH Toolbox Cognition Battery	Battery of cognitive tests recommended for ages $\geq 7$ y; consists of tests of multiple constructs; it yields individual measure scores and these summary scores: Education, Handedness, Attention (Flanker Inhibitory Control and Attention Test), Episodic Memory (Picture Sequence Memory Test, and Auditory Verbal Learning Test), Executive Function (Dimensional Change Card Sort Test, Flanker Inhibitory Control and Attention Test), Language (Picture Vocabulary Test, Oral Reading Recognition Test), Processing Speed (Pattern Comparison Processing Speed Test), Working Memory (List Sorting Working Memory Test)
Pre/Post Treatment Expectations and Experience Questionnaire (adolescent and parent)	Assessment of patient and parent impressions and expectations and integrity of blinding by asking adolescents and parents to guess their study arm assignment

Pubertal Development Scale and Tanner staging	Self-report questionnaire and line drawings used to evaluate level of pubertal development
Transcranial Magnetic Stimulation Safety Screen (TASS)	Safety screen completed before TMS to confirm patient safety for TMS
Young Mania Rating Scale (YMRS)	An 11-item measure used to assess for manic symptoms; if the YMRS is positive, a MINI or MINI-KID will be repeated to evaluate for mania, and if the study participant meets full <i>DSM-5</i> criteria for mania or hypomania, that person will be discontinued from the study and followed up clinically
TMS neurophysiology measures	TMS-EMG (LICI-100) and TMS-EEG (N45 and N100) neurophysiology measures (biomarkers of cortical inhibition and activity)

---

1198 Abbreviations: aTBS, accelerated theta burst stimulation; *DSM-5*, *Diagnostic and*  
1199 *Statistical Manual of Mental Disorders* (Fifth Edition); LICI-100, long-interval  
1200 intracortical inhibition at an interstimulus interval of 100 ms; NIH, National Institutes  
1201 of Health; N45, 45 ms after stimulation; N100, 100 ms after stimulation; TMS,  
1202 transcranial magnetic stimulation; TMS-EEG, TMS and electroencephalography;  
1203 TMS-EMG, TMS and electromyography.

1204

1205 **Box. Inclusion and Exclusion Criteria**

---

**Inclusion criteria:**

- Age 12-18 y
- Willingness and ability to give informed consent if aged 18 y or if <18 y, to assent (with consent given by a parent or legal guardian)
- Diagnosis of major depressive disorder (MDD) based on the criteria of the *Diagnostic and Statistical Manual for Mental Disorders* (Fifth Edition) for all participants and at screening the Mini-International Neuropsychiatric Interview (MINI) for Children and Adolescents (MINI-KID) for participants aged 12-17 or the MINI for participants who are 18
- Current episode of MDD lasting at least 4 weeks but <3 y
- Depressive symptom severity as shown by a total Children's Depression Rating Scale Revised (CDRS-R) score  $\geq 40$
- Suicidal ideation score  $\geq 3$  on item 13 of the CDRS-R
- Minimum score of 1 ("wish to be dead") on the Columbia–Suicide Severity Rating Scale (C-SSRS) severity of ideation subscale
- No demonstrated improvement by 25% or more in depressive symptom severity between screening evaluation and baseline
- Eligibility for transcranial magnetic stimulation (TMS) based on safety criteria
- Willingness to use a medically acceptable form of birth control during the 10-d treatment course if female and of childbearing potential

---

**Exclusion criteria:**

---



- 
- Diagnosis of a psychotic disorder, bipolar disorder, anorexia nervosa, bulimia nervosa, or substance use disorder (except caffeine and tobacco) within the past year
  - Lifetime diagnosis of a psychotic disorder, including schizophrenia, MDD with psychotic features, and bipolar disorder with psychotic features, confirmed by a research screening interview
  - IQ <70<sup>a</sup>
  - Positive urine drug screen at baseline
  - History of epilepsy or unexplained seizures or any other neurologic condition that includes a history of seizures
  - Family history of epilepsy
  - Use of medications that lower the seizure threshold (eg, neuroleptic agents and tricyclic antidepressants)
  - History of any treatment with electroconvulsive therapy or TMS
  - Use of any investigational drug within 4 wk of baseline
  - Prior brain surgery
  - Risk of increased intracranial pressure (eg, brain tumor) or a history of increased intracranial pressure
  - Lifetime history of head trauma with loss of consciousness for >5 min
  - Any true-positive findings on the Transcranial Magnetic Stimulation Safety Screen
  - Pregnancy or nursing
  - Conductive, ferromagnetic, or other magnetic-sensitive metals in the head within 30 cm of the treatment coil (excluding the mouth) that cannot be safely removed (eg, cochlear implants, vagus nerve
-

---

stimulators, deep brain stimulators, implanted electrodes/stimulators, aneurysm clips or coils, stents, bullet fragments, jewelry, and hair barrettes)

- Any implanted stimulator or other implant controlled by physiologic signals, including a vagus nerve stimulator, spinal cord stimulator, peripheral nerve stimulator, defibrillator, or pacemaker
- Implanted medication pump
- Cerebrovascular disease, cerebral aneurysm, dementia, movement disorder, or repetitive or severe head trauma, or primary or secondary tumors in the central nervous system
- History of severe headaches within the previous year
- Vascular, traumatic, tumoral, infectious, or metabolic lesions of the brain, even without a history of seizure or without anticonvulsant medication
- An unstable medical illness
- Improvement in depressive symptom severity between screening and baseline by  $\geq 25\%$
- Inability to adhere to the protocol

---

1206 <sup>a</sup> If a clinical concern exists about IQ, participants will be  
1207 psychometrically assessed with the Slosson Intelligence Test–Revised,  
1208 3rd edition (Slosson RL. Slosson Intelligence Test-Revised. 3rd ed.  
1209 Revised by Nicholson CL, Hibpsman TL, Supplementary Manual by  
1210 Larson S. East Aurora, NY: Slosson Educational Publications Inc).

1211

## Legend

1212 **Figure.** Study Schema.

1213 aTBS, accelerated theta burst stimulation; CDRS-R, Children's Depression

1214 Rating Scale Revised; C-SSRS, Columbia–Suicide Severity Rating Scale;

1215 LICI, long-interval intracortical inhibition; MINI, Mini-International


1216 Neuropsychiatric Interview; N45, TMS-EEG evoked potential at 45

1217 milliseconds; N100, TMS-EEG evoked potential at 100 milliseconds; TBS,

1218 theta burst stimulation; TMS-EEG, transcranial magnetic stimulation and

1219 electroencephalography; TMS-EMG, transcranial magnetic stimulation and

1220 electromyography.



Figure